# IRS Files First Response to Common Industry 280E Arguments > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/irs-section-280e-tax-deductions-cannabis/ > **Published:** 2026-03-12T22:50:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:08:21-04:00 > **Clinical Summary:** Explore IRS Section 280E tax deductions cannabis impact and how it affects cannabis business profitability and patient access. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyIndustryResearch Why This Matters The IRS’s response to Section 280E tax deduction arguments directly impacts cannabis business profitability and operational costs, which can influence product pricing and patient access to legal cannabis. Clinicians should understand that tax burden on dispensaries may affect whether patients can afford cannabis treatments or whether certain products remain available in their market. If Section 280E is modified through regulatory or legislative changes prompted by these IRS responses, it could reduce business costs and potentially improve patient access to standardized, regulated cannabis products. Clinical Summary The IRS has issued its first formal response to industry arguments challenging Internal Revenue Code Section 280E, which prohibits tax deductions for businesses trafficking in Schedule I controlled substances, including cannabis. The [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) has increasingly argued that cannabis should be reclassified to Schedule III based on a Department of Health and Human Services study supporting this change, which would theoretically allow businesses to claim standard business tax deductions. However, the IRS’s position indicates that Schedule I classification remains the controlling legal standard for tax purposes regardless of pending reclassification discussions, meaning cannabis businesses cannot currently deduct ordinary business expenses from federal taxes. This creates a significant and continuing financial burden for legal cannabis retailers and producers operating in compliant state markets. Clinicians should be aware that the high tax burden on cannabis businesses contributes to elevated retail prices and supply chain costs that may limit patient access to cannabis products, particularly for lower-income patients. Physicians should understand that cannabis scheduling and tax policy directly impact their patients’ ability to afford legal products and may inadvertently incentivize use of unregulated alternatives. Dr. Caplan’s Take “The IRS’s position on 280E tax deductions reflects a deeper problem: we cannot practice [evidence-based medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/) or build a legitimate pharmaceutical industry when federal scheduling prevents us from conducting the research that would settle these questions definitively. Until cannabis moves off Schedule I, physicians like myself will continue operating in a legal gray zone that ultimately harms patients who deserve transparent, regulated access to treatments we’re already prescribing.” Clinical Perspective The IRS’s first formal response to [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) arguments regarding Section 280E tax deductions highlights an ongoing tension between federal scheduling and business operations that clinicians should understand when counseling patients about the cannabis market and product safety. While the rescheduling debate hinges partly on HHS pharmacological evidence, the tax code implications create financial pressure on cannabis businesses that may inadvertently affect product quality, testing standards, and consumer safety—factors that influence what patients are actually purchasing and consuming. Clinicians need awareness that businesses operating under severe tax burdens may have reduced resources for third-party testing, quality assurance, and adverse event reporting, potentially obscuring the true safety and efficacy profile of cannabis products their patients use. Additionally, the current regulatory fragmentation means that clinical guidance must remain cautious and individualized, since product composition and contamination risks vary widely depending on state and local oversight. Understanding these industry and tax pressures provides helpful context when discussing 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+IRS+Files+First+Response+to+Common+Industry+280E+Arguments+%7C+Harris+Beach+Murtha+-+JDSupra+%40drcaplan&url=https%3A%2F%2Fwww.jdsupra.com%2Flegalnews%2Firs-files-first-response-to-common-9270378%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.jdsupra.com%2Flegalnews%2Firs-files-first-response-to-common-9270378%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+IRS+Files+First+Response+to+Common+Industry+280E+Arguments+%7C+Harris+Beach+Murtha+-+JDSupra+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.jdsupra.com%2Flegalnews%2Firs-files-first-response-to-common-9270378%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [In the Mix: 7 More Articles — March 12, 2026](https://cedclinic.com/cannabis-regulatory-uncertainty-clinical-implications/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.jdsupra.com/legalnews/irs-files-first-response-to-common-9270378/](https://www.jdsupra.com/legalnews/irs-files-first-response-to-common-9270378/) Further Reading Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) Evidence Watch[`Cannabinoids and PTSD: Clinical Research on Trauma Care`](https://cedclinic.com/cannabinoids-and-ptsd-trauma-care-research/) Cannabis Policy Wire[Policy Watch: 25 Regulatory Updates — March 12, 2026](https://cedclinic.com/dea-scheduling-synthetic-drugs-march-12-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal Reclassification Reshapes Risks for Medical Marijuana Businesses](https://cedclinic.com/federal-reclassification-reshapes-risks-for-medical-marijuana-businesses/) Learn how federal cannabis reclassification impacts business risks and tax considerations for [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) operators. [Read More](https://cedclinic.com/federal-reclassification-reshapes-risks-for-medical-marijuana-businesses/) [Ohio Tax Department Amends Adult-Use Cannabis Tax Rules](https://cedclinic.com/ohio-tax-department-amends-adult-use-cannabis-tax-rules/) Updates on Ohio's adult-use cannabis tax regulations and their implications for businesses and patients. [Explore Updates](https://cedclinic.com/ohio-tax-department-amends-adult-use-cannabis-tax-rules/) [US Cannabis Rescheduling: A Victory or a Federal Trap?](https://cedclinic.com/cannabis-federal-policy-impacts-patient-access/) An analysis of cannabis rescheduling efforts and their potential effects on taxation and industry operations. [Learn More](https://cedclinic.com/cannabis-federal-policy-impacts-patient-access/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).